Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of remimazolam tosilate combined with sufentanil in cirrhotic patients undergoing painless gastroscopy
ChiCTR2100041845Phase 4Recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in Cirrhosis, None and anxiety disorder, sponsored by Beijing YouAn Hospital. Primary endpoints: Physical activity during gastroscopy and ED50 of remimazolam tosilate with sufentanil. Started Feb 2021; status: recruiting.
02
Drugs
remimazolam
03
Conditions
Cirrhosisanxiety disorder
Beyond the preview
Go deeper on ChiCTR2100041845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041845.